Hearing Loss Trial, Recruiting (NCT06226558)

Hearing Loss Trial, Recruiting NCT06226558 Sponsor: Stony Brook University Condition: Hearing Loss

Printed from Voxsanity (voxsanity.com.au) — NCT06226558 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hearing Loss

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Your baby was born in New York State between September 27, 2023 and October 1, 2024
Your baby received an evaluation for congenital CMV (a virus that can be passed from mother to baby before birth) at an officially designated New York State referral clinic
Your family is willing and able to take part in all parts of the study
Your baby falls into one of these four groups:
- Group 1: Your baby's newborn screening test was positive for CMV, and a follow-up confirmation test was also positive
- Group 2: Your baby's newborn screening test was negative for CMV, but a follow-up confirmation test came back positive
- Group 3: Your baby's newborn screening test was positive for CMV, but a follow-up confirmation test came back negative (sometimes called a "false positive")
- Group 4: Your baby was born prematurely (before 37 weeks), had a positive CMV result on any newborn screen taken before 44 weeks of age, and had a follow-up confirmation test that was also positive within 14 days of that screen

Who may not be able to join:

Parents or guardians who do not want their baby to take part in the long-term follow-up portion of the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 631-444-7692

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06226558

Sponsor: Stony Brook University

Phase: Not Applicable

Status: Recruiting

Condition: Hearing Loss

Trial contact: 631-444-7692

More information: https://clinicaltrials.gov/study/NCT06226558

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Your baby was born in New York State between September 27, 2023 and October 1, 2024
Your baby received an evaluation for congenital CMV (a virus that can be passed from mother to baby before birth) at an officially designated New York State referral clinic
Your family is willing and able to take part in all parts of the study
Your baby falls into one of these four groups:
- Group 1: Your baby's newborn screening test was positive for CMV, and a follow-up confirmation test was also positive
- Group 2: Your baby's newborn screening test was negative for CMV, but a follow-up confirmation test came back positive
- Group 3: Your baby's newborn screening test was positive for CMV, but a follow-up confirmation test came back negative (sometimes called a "false positive")
- Group 4: Your baby was born prematurely (before 37 weeks), had a positive CMV result on any newborn screen taken before 44 weeks of age, and had a follow-up confirmation test that was also positive within 14 days of that screen

Who may not be able to join:

Parents or guardians who do not want their baby to take part in the long-term follow-up portion of the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Stony Brook University

Registry

ClinicalTrials.gov

Start date

1 February 2024

Est. completion

1 October 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Congenital CMV infection rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov